Neurophet is a company that specializes in the development of advanced software solutions for the healthcare industry, focusing on diagnostic and predictive analytics in the field of neurology.

Junkil Been

Donghyeon Kim

Neurophet

Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed the next-generation neuro-navigation system.

Major products include brain MRI imaging analysis and interpretation software "Neurophet AQUA", brain PET scan analysis (PET tracer deposition) software "Neurophet SCALE PET", brain electric and magnetic stimulation simulation software "Neurophet tES/TMS Lab", and a brain region of interest analysis research tool "Neurophet SegPlus".

Neurophet has set its top priority to helping patients suffering from brain diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.


As the notification last week, this page will be closed on Oct. 6th. Please visit our new official LinkedIn page and follow us to keep communicate!🙌 
👉 https://lnkd.in/g7bhFEuw

Thank you everyone, for your interest and support!💗 
 
Hope you have enjoyed Neurophet’s news, events, and health related information, etc. so far on our LinkedIn page.  

You might notice that there are two different pages of Neurophet, and we decided to integrate these pages since they could be confusing for users.  
This page will be closed on Oct. 6th, and I’d love to invite you to the new official Neurophet’s LinkedIn page. Please visit and follow our page! 
👉 https://lnkd.in/g7bhFEuw

We promise to continuously provide the latest news and interesting information. Stay tuned for more to come!😊  

[#Neurophet_Conference] 

Neurophet participated in the International Society for Magnetic Resonance in Medicine (ISMRM) JPC 2023 in Japan and introduced the importance and necessity of using brain image analysis software.📊  

Professor Hyun Kook Lim, CMO of Neurophet and head of Catholic Dementia Cognitive Disorder Center, presented why quantification software is needed for brain image analysis and the advantages of using Neurophet AQUA in the medical field.👨‍⚕️ 

Neurophet is actively engaged in sales and marketing activities to supply Neurophet AQUA to the Japanese market. 

Check out the pictures of the conference!  

#Neurophet #ISMRM_JPC_2023 #HyunKookLim #CMO #Japan #Nagano #Luncheon_Seminar #Neurophet_AQUA 

[#World_Alzheimers_Day] 

Every September 21st is World Alzheimer's Day, established by Alzheimer's Disease International (ADI) in collaboration with the World Health Organization (WHO).  

Especially this year, there were many global issues related to dementia. There's no cure for Alzheimer's, but the launch of Alzheimer's treatment #Lecanemab and the revision of Alzheimer’s diagnostic criteria, etc. would become available options to slow down disease progression, to cope with symptoms, to early diagnose and to improve quality of life. 

Neurophet continues to develop and collaborate on technology, for our technology and products could be used in the right place to overcome dementia. 

#Neurophet #World_Alzheimers_Day #Alzheimers #Lecanemab #Alzheimers_treatment  

Metric
Company Name	Neurophet
Symbol
MSH ID	COM:NEUROPHET
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare Technology
Country	KR
Stage
Employee Count	5
Website	neurophet.com
LinkedIn	neurophet-en
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:NEUROPHET

Neurophet

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue